| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 02/10/2005 | US20050031542 using carbocyanine dyes; photodynamic therapy; supplying to tumors |
| 02/10/2005 | US20050029705 Extrusion die |
| 02/10/2005 | DE3823105B4 Dolastatin 10, Verfahren zu seiner Gewinnung, und es enthaltende pharmazeutische Zusammensetzungen Dolastatin 10, process for its production, and pharmaceutical compositions containing it |
| 02/10/2005 | DE10333406A1 T-regulatorische-Zellen enthaltend Galectine zur Therapie und Diagnose von Erkrankungen T-regulatory cells containing galectins for the therapy and diagnosis of diseases |
| 02/10/2005 | DE10331957A1 Pharmarzeutischer Wirkstoff gegen Magengeschwüre Pharmarzeutischer drug for stomach ulcers |
| 02/10/2005 | DE10221194B4 Hyaluronidasehaltiges Hautpflegemittel Hyaluronidasehaltiges skin care products |
| 02/10/2005 | CA2574733A1 Method for the production of cyclic molecules |
| 02/10/2005 | CA2546497A1 Casein hydrolyzate, process for producing the same and use thereof |
| 02/10/2005 | CA2537899A1 Tissue-specific targeting of therapeutic and imaging agents to caveolae |
| 02/10/2005 | CA2534991A1 Short interfering rna as an antiviral agent for hepatitis c |
| 02/10/2005 | CA2534711A1 Combination therapies for multiple sclerosis |
| 02/10/2005 | CA2534461A1 An agent for preventing and/or treating hematologic malignancies |
| 02/10/2005 | CA2534432A1 Methods for treating diabetes and related disorders using pde10a inhibitors |
| 02/10/2005 | CA2534327A1 Trans-capsular administration of high specificity cytokine inhibitors into orthopedic joints |
| 02/10/2005 | CA2533820A1 Spatially-defined macrocycles incorporating peptide bond surrogates |
| 02/10/2005 | CA2533818A1 Spatially-defined macrocyclic compounds useful for drug discovery |
| 02/10/2005 | CA2533789A1 Epha2 t-cell epitope agonists and uses therefor |
| 02/10/2005 | CA2533781A1 Cyclic cadherin analogues comprising the sequence hav for modulating the migration of vascular smooth muscle cells |
| 02/10/2005 | CA2533687A1 A method of producing an anticoagulation effect |
| 02/10/2005 | CA2533423A1 Use of rnai inhibiting parp activity for the manufacture of a medicament for the treatment of cancer |
| 02/10/2005 | CA2532870A1 Use of soluble cd164 in inflammatory and/or autoimmune disorders |
| 02/10/2005 | CA2532742A1 Use of a pak inhibitor for the treatment of a joint disease |
| 02/10/2005 | CA2532537A1 Biologically non-degradable peptides and their use as angiotensin converting enzyme inhibitors, drugs and functional foods |
| 02/10/2005 | CA2531988A1 Novel insulin derivatives |
| 02/10/2005 | CA2531320A1 Reversibly immortalised olfactory ensheathing glia and their use to promote neuronal regeneration |
| 02/10/2005 | CA2531231A1 Uranium-chelating peptides and uses thereof |
| 02/10/2005 | CA2531227A1 Methods and apparatus for creating particle derivatives of hdl with reduced lipid content |
| 02/10/2005 | CA2529798A1 Methods of treating hepatocellular carcinoma with zvegf3 antagonists |
| 02/10/2005 | CA2527861A1 Alkynyl aryl carboxamides |
| 02/09/2005 | EP1505154A1 Vector with modified protease-dependent tropism |
| 02/09/2005 | EP1505062A1 Heterocyclic derivatives and their use as antithrombotic agents |
| 02/09/2005 | EP1504774A1 Artificial extracellular matrix and process for producing the same |
| 02/09/2005 | EP1504764A1 Treatment of liver fibrosis with antagonists of alpha V beta 6 integrin |
| 02/09/2005 | EP1504268A2 Diagnostics and therapeutics for diseases associated with oxytocin receptor (oxtr) |
| 02/09/2005 | EP1504124A1 Ldl receptor-related proteins 1 and 2 and treatment of bone or cartilage conditions |
| 02/09/2005 | EP1504099A2 Novel nucleic acids and polypeptides |
| 02/09/2005 | EP1504098A2 A method for in vitro molecular evolution of protein function |
| 02/09/2005 | EP1504089A2 Allergen mutants |
| 02/09/2005 | EP1504037A2 Ferritin fusion proteins for use in vaccines and other applications |
| 02/09/2005 | EP1504035A2 Antibodies specific for human cd22 and their therapeutic and diagnostic uses |
| 02/09/2005 | EP1504033A2 Connective tissue stimulating peptides |
| 02/09/2005 | EP1504027A2 Adipocyte complement related protein zacrp8 |
| 02/09/2005 | EP1504026A2 Therapeutic polypeptides, nucleic acids encodings same, and methods of use |
| 02/09/2005 | EP1503802A2 Controllably degradable polymeric biomolecule or drug carrier and method of synthesizing said carrier |
| 02/09/2005 | EP1503801A2 Non-invasive delivery of polypeptides through the blood-brain barrier, and in vivo selection of endocytotic ligands |
| 02/09/2005 | EP1503798A1 Stabilised solid compositions of modified factor vii |
| 02/09/2005 | EP1503795A2 Use of heat shock proteins to enhance efficacy of antibody therapeutics |
| 02/09/2005 | EP1503794A1 Methods of treatement using ctla-4 antibodies |
| 02/09/2005 | EP1503791A2 Methods of therapy for inducing tolerance |
| 02/09/2005 | EP1503790A1 Intracranial treatment of neuropsychiatric disorders by clostridial neurotoxins such as botulinum toxin |
| 02/09/2005 | EP1503789A2 Vascularization enhanced graft constructs |
| 02/09/2005 | EP1503788A2 Treatment of alpha-galactosidase a deficiency |
| 02/09/2005 | EP1503787A1 Compositions and methods for diagnosis and treatment of cardiovascular disorders |
| 02/09/2005 | EP1503786A2 A method of inhibiting the emigration of cells from the intravascular compartment into tissues |
| 02/09/2005 | EP1503785A2 Novel tissue factor targeted thrombomodulin fusion proteins as anticoagulants |
| 02/09/2005 | EP1503784A2 Treatment and inhibition of ocular infections and wounds by cap37 and cap37 peptides |
| 02/09/2005 | EP1503783A1 A combination product comprising an anti-coagulant and anti-arrhythmic oxabispidenes |
| 02/09/2005 | EP1503782A1 A combination product comprising melagatran and an anti-arrhythmic oxabispidenes |
| 02/09/2005 | EP1503780A2 Androgen-regulated pmepa1 gene and methods of using the same to inhibit cancer cell growth |
| 02/09/2005 | EP1503779A2 Methods for slowing senescence and treating and preventing diseases associated with senescence |
| 02/09/2005 | EP1503776A1 Method of enhancing biological activity of plant extracts |
| 02/09/2005 | EP1503767A2 Compositions and methods for treatment of vitamin d deficiency |
| 02/09/2005 | EP1503766A2 Compositions and methods for treating emphysema |
| 02/09/2005 | EP1503758A1 Methods of modulating smooth muscle contractility |
| 02/09/2005 | EP1503757A2 Tyrosine kinase inhibitors |
| 02/09/2005 | EP1503749A2 Methionine aminopeptidase-2 inhibitors and methods of use thereof |
| 02/09/2005 | EP1503745A2 15625 receptor, a novel g-protein coupled receptor |
| 02/09/2005 | EP1503735A2 A direct cellular energy delivery system |
| 02/09/2005 | EP1503734A2 Methods and apparatus for modifying properties of the bbb and cerebral circulation by using the neuroexcitatory and/or neuroinhibitory effects of odorants on nerves in the head |
| 02/09/2005 | EP1503730A2 Growth factor delivery system for the healing of wounds and the prevention of inflammation and disease |
| 02/09/2005 | EP1503714A2 Low profile combination device for gastrostomy or jejunostomy applications having anti-granuloma formation characteristics |
| 02/09/2005 | EP1503652A2 Vascularization enhanced graft constructs |
| 02/09/2005 | EP1456223A4 Rapidly maturing fluorescent proteins and methods for using the same |
| 02/09/2005 | EP1453816A4 Phenoxy amine compounds and compositions for delivering active agents |
| 02/09/2005 | EP1432436A4 Nutrient therapy for immuno-compromised patients |
| 02/09/2005 | EP1287159A4 Enzymatic treatment of whey proteins for the production of antihypertensive peptides, the resulting products and treatment of hypertension in mammals |
| 02/09/2005 | EP1282633A4 Mammalian soluble adenylyl cyclase |
| 02/09/2005 | EP1255850A4 AMPLIFICATION OF $i(CYP24) AND USES THEREOF |
| 02/09/2005 | EP1242121B1 Polypeptide compositions with improved stability |
| 02/09/2005 | EP1242112A4 Particulate drug-containing products and method of manufacture |
| 02/09/2005 | EP1210119B1 Pharmaceutical compositions for oral and topical administration |
| 02/09/2005 | EP1082875A4 Improved brush block housing for propeller deicing system |
| 02/09/2005 | EP1080104B1 Certain heteroaryl substituted thiol inhibitors of endothelin-converting enzyme |
| 02/09/2005 | EP1079813B1 Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces |
| 02/09/2005 | EP1078099A4 Identifying peptide ligands of target proteins with target complementary library technology (tclt) |
| 02/09/2005 | EP1056860B1 High affinity humanized anti-tag-72 monoclonal antibodies |
| 02/09/2005 | EP1037659A4 Fibrinolytic inhibitor for sealant |
| 02/09/2005 | EP0700438B1 Opioid receptors: compositions and methods |
| 02/09/2005 | EP0383799B2 Adheson variants |
| 02/09/2005 | EP0365597B2 Improved processes for the treatment of vascular disease |
| 02/09/2005 | CN1578840A Aptamers containing sequences of nucleic acid or nucleic acid analogues bound homologously, or in novel complexes |
| 02/09/2005 | CN1578838A Method and means for producing protein with prospective post-translation modification |
| 02/09/2005 | CN1578786A Linear basic compounds having nk-2 antagonist activity and formulations thereof |
| 02/09/2005 | CN1578781A 1, 8 naphthyridine derivatives and their use to treat diabetes and related disorders |
| 02/09/2005 | CN1578780A 1, 6-naphthyridine derivatives as antidiabetics and pharmaceutical compositions containing them |
| 02/09/2005 | CN1578670A Use of lactalapoprotein in prevention and treatment of microbial or virus infection |
| 02/09/2005 | CN1578650A Compositions for the treatment of infectious diseases |
| 02/09/2005 | CN1578647A Implantable and sealable system for unidirectional delivery of therapeutic agents to tissues |
| 02/09/2005 | CN1575819A Use of melanoma differentiation associated gene (mda-7) for reversing cancerous phenotype |
| 02/09/2005 | CN1575816A Compounds for the treatment of female sexual dysfunction |